Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del/minimal function genotype.
Respir Med. 2021 Nov-Dec;189:106646. doi: 10.1016/j.rmed.2021.106646. Epub 2021 Oct 12.
Respir Med. 2021.
PMID: 34673344
Free article.
Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study.
Carnovale V, Iacotucci P, Terlizzi V, Colangelo C, Ferrillo L, Pepe A, Francalanci M, Taccetti G, Buonaurio S, Celardo A, Salvadori L, Marsicovetere G, D'Andria M, Ferrara N, Salvatore D.
Carnovale V, et al. Among authors: buonaurio s.
J Clin Med. 2022 Feb 16;11(4):1021. doi: 10.3390/jcm11041021.
J Clin Med. 2022.
PMID: 35207295
Free PMC article.
Item in Clipboard
Clinical outcomes of digital health in adults with cystic fibrosis.
Carnovale V, Iacotucci P, Qiao D, Ferrillo L, Somma J, Buonaurio S, Marcella d'Ippolito, Celardo A, Savi D.
Carnovale V, et al. Among authors: buonaurio s.
Respir Med. 2022 Oct;202:106970. doi: 10.1016/j.rmed.2022.106970. Epub 2022 Aug 28.
Respir Med. 2022.
PMID: 36058164
Item in Clipboard
Cite
Cite